Severe Combined Immunodeficiency (SCID) Diagnosis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hospitals is the fastest growing sector, North America is the largest market

The global market for Severe Combined Immunodeficiency (SCID) diagnosis is projected to expand significantly, growing from USD 189.98 Million in 2025 to USD 323.74 Million by 2031, at a compound annual growth rate (CAGR) of 9.29%. This market focuses on identifying SCID, a severe primary immunodeficiency, utilizing advanced techniques like T-cell receptor excision circle (TREC) assays, flow cytometry, and next-generation genetic sequencing. Its growth is primarily fueled by the increasing global implementation of government-mandated newborn screening initiatives and the broader adoption of sophisticated genomic tools, which facilitate earlier and more effective interventions. Notably, a 2025 update from the International Union of Immunological Societies officially categorized 559 distinct inborn errors of immunity, enhancing diagnostic precision for intricate conditions such as SCID.

However, a major obstacle hindering market expansion is the pronounced disparity in diagnostic infrastructure between developed and developing countries. The substantial costs associated with essential confirmatory molecular testing and a scarcity of specialized immunologists in areas with limited resources pose significant impediments to widespread implementation. This imbalance results in delayed diagnoses in underserved regions, thereby preventing prompt access to crucial life-saving therapies and ultimately constraining the overall growth potential of the global diagnosis market.

Market Drivers

The primary impetus behind the SCID diagnosis market is the global expansion of mandatory newborn screening initiatives, which are transforming detection from symptomatic to pre-symptomatic identification. Health agencies are incorporating T-cell receptor excision circle (TREC) assays into routine neonatal screening panels, consequently increasing the demand for diagnostic consumables and robust confirmatory infrastructure. This proactive approach ensures early identification in infants, a crucial factor for successful transplantation outcomes. As an example, the UK National Screening Committee reported in March 2025 that over one million babies have been screened for SCID since the NHS in-service evaluation began. Moreover, such programs refine prevalence data; for instance, expanded screening in Ukraine in 2025, as cited by Frontiers, established a SCID incidence of 1 in 57,000 live births, thereby validating universal testing protocols.

Concurrently, the rise of innovative gene therapies is significantly boosting the market by underscoring the importance of precise molecular characterization. With regulatory approvals for gene-specific interventions targeting conditions like ADA-SCID or X-linked SCID, clinicians are increasingly required to employ next-generation sequencing to pinpoint exact genetic mutations. This precise identification allows for tailored treatments, moving beyond generalized approaches, and thus intensifies the demand for comprehensive genetic panels. The rapid progress in therapeutic innovation is evident in a July 2025 report from the Innovative Genomics Institute, which highlighted the development and delivery of a custom in vivo CRISPR therapy within just six months, demonstrating the accelerated timeline for personalized medicine that relies heavily on accurate diagnosis.

Market Challenges

A substantial impediment to the growth of the Global SCID Diagnosis Market is the profound disparity in diagnostic infrastructure and economic capabilities between developed and developing nations. While affluent regions are progressively adopting advanced genomic tools, a considerable portion of the global market remains untapped due to the prohibitive expenses involved in establishing molecular testing facilities and a critical shortage of specialized immunologists in resource-constrained environments. This imbalance precludes the broad implementation of mass screening programs, thereby preventing diagnostic manufacturers from entering large, emerging markets. As a direct result, the global utilization of testing kits and sequencing assays is severely limited, leading to a significant loss of potential revenue for the industry.

Further emphasizing the scale of this market constraint, collaborative findings published in 2024 by the International Patient Organisation for Primary Immunodeficiencies (IPOPI) revealed that only 42 countries worldwide had initiated SCID newborn screening at a national, regional, or pilot level by mid-year. This statistic distinctly highlights that the vast majority of nations lack the essential frameworks to systematically detect SCID, which directly curtails the potential customer base for diagnostic companies.

Market Trends

A significant trend reshaping laboratory workflows is the widespread adoption of multiplex assays for simultaneously screening for SCID and Spinal Muscular Atrophy (SMA), which consolidates detection into a single, efficient reaction. Laboratories are increasingly transitioning from single-target tests to multiplex real-time PCR assays capable of screening for both T-cell Receptor Excision Circles (TREC) and Survival Motor Neuron 1 (SMN1). This shift notably improves cost-effectiveness and reduces diagnostic turnaround times. Such integrated approaches are being rigorously validated through extensive public health evaluations aimed at confirming the viability of dual-target protocols without disrupting existing newborn screening throughput. For instance, SMA UK reported in August 2025 that its national in-service evaluation successfully involved 32,274 participants to assess the clinical effectiveness of identifying SMA concurrently with severe immunodeficiencies using this integrated screening infrastructure.

Furthermore, the growing demand for precision genotyping, spurred by the development of gene-specific therapies, is accelerating the early integration of advanced genomic sequencing into the diagnostic process. As potentially curative interventions such as gene editing become available, acquiring an exact molecular genotype is now essential for determining patient eligibility and guiding appropriate treatment strategies, rather than solely depending on phenotypic data. This critical need is prompting national initiatives to employ whole genome sequencing for detecting rare conditions, including SCID, to ensure no underlying genetic cause is overlooked. As an example, Genomics England announced in October 2025 that its "Generation Study" has enrolled 25,000 newborns to evaluate the effectiveness of whole genome sequencing in identifying over 200 rare genetic conditions, thereby setting a new benchmark for precision diagnosis.

Key Market Players

• ARCHIMED SAS
• PerkinElmer LAS Inc
• Health Research, Inc
• Winfertility Inc.
• Portea Medical
• LaCAR MDX Technologies
• Labsystems Diagnostics Oy
• Devyser Diagnostics
• Revcovi
• Leadiant Biosciences Inc.

Report Scope

In this report, the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Severe Combined Immunodeficiency (SCID) Diagnosis Market, by Disease Type:

• X-linked SCID
• ADA-SCID
• others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, by Test Type:

• TREC
• Complete blood count (CBC)
• Genetic Test
• Biochemical Test
• others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, by End User:

• Hospitals
• Diagnostic and Research Laboratories
• Others

Severe Combined Immunodeficiency (SCID) Diagnosis Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Severe Combined Immunodeficiency (SCID) Diagnosis Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.